ATF6α Activation Enhances Survival against Chemotherapy and Serves as a Prognostic Indicator in Osteosarcoma

ATF6α Activation Enhances Survival against Chemotherapy and Serves as a Prognostic Indicator in Osteosarcoma

Patients with metastatic or relapsed/refractory osteosarcoma (OS) have a 5-year survival rate of <30%. This has remained unchanged over several decades. One of the factors contributing to lack of improvement in survival is the development of chemoresistance. Hence, elucidating and targeting the m...

Full description

Bibliographic Details
Main Authors: Suma Yarapureddy, Jazmine Abril, Janet Foote, Saravana Kumar, Omar Asad, Veena Sharath, Janine Faraj, Dustin Daniel, Paul Dickman, Andrea White-Collins, Pooja Hingorani, Aparna R Sertil
Format: Article
Language:English
Published: Elsevier 2019-06-01
Series:Neoplasia: An International Journal for Oncology Research
Online Access:http://www.sciencedirect.com/science/article/pii/S147655861830527X

Similar Items

Similar Items